A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 on ClinicalTrials.gov · last registry update 2026-09-14
Finished 21 July 2026, after enrolling 712 people. Primary outcome, as filed: Change from Baseline in Apnea-Hypopnea Index (AHI). orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 3 times since then.
- Status
- COMPLETED
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 712
- Started
- 2024-10-22
- Primary completion
- 2026-07-21 actual
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-14 | Reporting date moved | 2026-11 → 2026-07-21 4 months earlier |
| 2026-09-14 | Status changed | ACTIVE_NOT_RECRUITING → COMPLETED |
| 2026-09-14 | Enrollment changed | 600 → 712 (+112) participants |
Primary outcome
Change from Baseline in Apnea-Hypopnea Index (AHI)
Conditions studied
OSA · Overweight or Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.